» Articles » PMID: 31191343

Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology

Overview
Journal Front Physiol
Date 2019 Jun 14
PMID 31191343
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure with preserved ejection fraction (HFpEF) is one of the largest unmet clinical needs in 21st-century cardiology. It is a complex disorder resulting from the influence of several comorbidities on the endothelium. A derangement in nitric oxide bioavailability leads to an intricate web of physiological abnormalities in the heart, blood vessels, and other organs. In this review, we examine the contribution of cardiac and noncardiac factors to the development of HFpEF. We zoom in on recent insights on the role of comorbidities and microRNAs in HFpEF. Finally, we address the potential of exercise training, which is currently the only available therapy to improve aerobic capacity and quality of life in HFpEF patients. Unraveling the underlying mechanisms responsible for this improvement could lead to new biomarkers and therapeutic targets for HFpEF.

Citing Articles

Soluble ST2: A Novel Biomarker for Diagnosis and Prognosis of Cardiovascular Disease.

Feng Y, He L Curr Med Sci. 2024; 44(4):669-679.

PMID: 39096477 DOI: 10.1007/s11596-024-2907-x.


Pathophysiology of Preeclampsia-Induced Vascular Dysfunction and Implications for Subclinical Myocardial Damage and Heart Failure.

Shaw L, Patel K, Lala-Trindade A, Feltovich H, Vieira L, Kontorovich A JACC Adv. 2024; 3(6):100980.

PMID: 38938863 PMC: 11198310. DOI: 10.1016/j.jacadv.2024.100980.


Hypertension and Heart Failure: From Pathophysiology to Treatment.

Gallo G, Savoia C Int J Mol Sci. 2024; 25(12).

PMID: 38928371 PMC: 11203528. DOI: 10.3390/ijms25126661.


Heart failure with preserved ejection fraction: implications for anaesthesia.

Shah A, Sabharwal N, Day J BJA Educ. 2024; 24(5):155-163.

PMID: 38646450 PMC: 11026937. DOI: 10.1016/j.bjae.2024.02.003.


Systemic inflammation predicts diastolic dysfunction in patients with sleep disordered breathing.

Hegner P, Wester M, Tafelmeier M, Provaznik Z, Klatt S, Schmid C Eur Respir J. 2024; 63(6).

PMID: 38636989 PMC: 11154749. DOI: 10.1183/13993003.00579-2024.


References
1.
Li J, Gall N, Grieve D, Chen M, Shah A . Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002; 40(4):477-84. DOI: 10.1161/01.hyp.0000032031.30374.32. View

2.
Brutsaert D . Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2002; 83(1):59-115. DOI: 10.1152/physrev.00017.2002. View

3.
Redfield M, Jacobsen S, Burnett Jr J, Mahoney D, Bailey K, Rodeheffer R . Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289(2):194-202. DOI: 10.1001/jama.289.2.194. View

4.
Hristov M, Erl W, Weber P . Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003; 23(7):1185-9. DOI: 10.1161/01.ATV.0000073832.49290.B5. View

5.
Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View